

Syntheses and analyses of conjugates 1 and 4

General

Where anhydrous solvents were required for reactions, MeOH and DMF were purchased (anhydrous) and used as received. DCM was doubly distilled (over CaH₂) before use and THF was obtained anhydrous and was used without further drying. All other solvents were dried using appropriate drying reagents. Fine chemicals were purchased from Aldrich-, Sigma- or Acros-Chemicals and were of the highest purity available. Reactions were monitored via thin layer chromatography (TLC) using pre-coated silica sheets with fluorescent indicator UV₂₅₄. Compound detection was achieved by UV absorption and by developing plates by staining with a molybdenum phosphate reagent (20 g ammonium molybdate and 0.4 g cerium^(IV) sulfate in 400 mL of 10% aqueous sulphuric acid) with subsequent heating.

Chromatographic purification was performed using silica gel 60A 'Davisil' (particle size 35-70µm) from Fisher Scientific, UK and silica gel 100 C18 reversed phase (particle size 40-63µm from Fluka Analytical, UK. Silica-based MPLC chromatography was carried out on the Büchi Sepacore system equipped with glass columns packed with LiChroprep Si 60 (15-25µm) from Merck, Darmstadt, Germany. Solvents for chromatography were used as received except for toluene and ethyl acetate, which were distilled before use. Gel permeation chromatography was carried out in the 1-10 mg scale on a XK 16/70 column (bed volume 130 mL), from Amersham packed with Sephadex G-10 (particle size 40-120µm) and 0.1 M NH₄HCO₃ as buffer. Detection was achieved using a differential refractometer from Knauer, Berlin, Germany.

¹H NMR, ¹³C NMR, ³¹P NMR and all multidimensional spectra were recorded on Varian VNMRs spectrometers (600 MHz, 500 MHz or 400 MHz). Chemical shifts in ¹H and ¹³C NMR spectra were referenced to the residual proton resonance of the respective deuterated solvents, CDCl₃ (7.26 ppm), D₂O (4.80 ppm) and CD₃OD (3.31 ppm) respectively. For ³¹P NMR spectra H₃PO₄ was used as external standard (0 ppm).

HR-ESI-MS spectra were recorded on a Bruker Daltonics Apex III in positive mode with MeOH and/or H₂O as solvent. Where possible, HR-ESI-MS has been used to characterise compounds which have been synthesised.

Target compound phospha-oseltamivir-biotin conjugate 1

Under an atmosphere of dry nitrogen, protected biotin-conjugate **4** (26 mg, 0.019 mmol) was dissolved in THF (1.5 mL), NEt₃ (0.37 mL, 0.27 mmol) and thiophenol (0.016 mL, 0.133 mmol) were added and the mixture was stirred for 48 h at room temperature. The same amounts of NEt₃ and thiophenol were added and stirring was continued for another 24 h when tlc indicated completion of the reaction. The solvents and reagents were removed *in vacuo* and the resulting crude product was taken up in water (2 mL), sonicated and filtered. The demethylated intermediate was purified by gel

permeation chromatography (0.1 M NH_4HCO_3) as detailed in ref. 6, and the resulting 13 mg (51%) were stirred in a solution of TFA/ H_2O (1:1) (1 mL) overnight. The solvent was then evaporated *in vacuo* and the residue was purified again by gel permeation chromatography (0.1 M NH_4HCO_3) to afford target compound **1** (8 mg, 66%).

^1H NMR (600 MHz, D_2O) δ_{H} : 0.89 – 1.00 (6 H, m, $-\text{OCH}(\text{CH}_2\text{CH}_3)_2$), 1.42 – 1.76 (18 H, bm, $-\text{OCH}(\text{CH}_2\text{CH}_3)_2$, $-\text{C}(\text{O})\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{NH}-$), 2.13 (3 H, s, $-\text{NHCOCH}_3$), 2.27, (2 H, m, $-\text{C}(\text{O})\text{CH}_2-$), 2.48, 2.59 (2 H, m, $\text{H}_{6\text{ax}}$, $\text{H}_{6\text{eq}}$), 2.85, 3.02 (2 H, d, dd, $J = 13.1$ Hz, $J = 5.0$, 13.2 Hz, $-\text{S}-\text{CH}_2-$), 3.25 (1H, $\text{OCH}(\text{CH}_2\text{CH}_3)_2$, 3.42-3.45 (3 H, $-\text{CH}_2\text{CH}_2\text{NH}-$, $-\text{S}-\text{CH}_2-$), 3.66 – 3.72 (4 H, m, $-\text{OCH}_2\text{CH}_2\text{NHCO}-$, $\text{NHCOCH}_2\text{CH}_2\text{O}-$), 3.74-3.77 (44H, $-\text{O}(\text{CH}_2\text{CH}_2)_{11}\text{O}-$), 3.79-3.90 (6H, m, $-\text{OCH}_2\text{CH}_2\text{NHCO}-$, $-\text{NHCOCH}_2\text{CH}_2\text{O}-$, H_4 , H_5), 3.98 (1H, m, H_3), 4.27 (2 H, m, $-\text{OCH}_2\text{CH}_2-$), 4.49 (1 H, m, $-\text{S}-\text{CH}-\text{CH}-\text{NHCO}-$), 4.67 (1 H, $-\text{S}-\text{CH}_2-\text{CH}-\text{NHCO}-$), 6.37 (1 H, d, $J_{\text{P-2}} = 19.06$ Hz, H_2).

^{13}C NMR (150.8 MHz, D_2O) δ_{C} : 8.93, 9.01 ($-\text{OCH}(\text{CH}_2\text{CH}_3)_2$), 22.72 ($-\text{NHCOCH}_3$), 25.12, 25.52, 25.59, 25.94, 26.12, 28.07, 28.25, 28.59, (3 biotin-C, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2-\text{CH}_2\text{CH}_2\text{NH}-$, $-\text{OCH}(\text{CH}_2\text{CH}_3)_2$), 30.26 ($-\text{OCH}_2\text{CH}_2-$), 35.83 (C-biotin), 36.51 (C_6), 39.63 (2 C-biotin), 49.6 (d, C_5), 53.52 (C_4), 55.73, 60.62, 62.45 (3C-biotin), 65.68, 67.23, 68.31, 69.26, 69.65, 69.79, 69.88, 70.03 ($-\text{OCH}_2\text{CH}_2\text{O}-$, $\text{OCH}_2\text{CH}_2\text{NHCO}-$, POCH_2- , $-\text{NHCOCH}_2\text{CH}_2-$), 76.28 (C_3), 84.51 ($-\text{OCH}(\text{CH}_2\text{CH}_3)_2$), 130.0 (C_1), 136.45 (C_2), 166.68 ($-\text{NH}-\text{C}(\text{O})-\text{NH}-$), 175.12 ($-\text{NHCOCH}_3$), 175.53 ($-\text{CH}_2-\text{C}(\text{O})\text{NH}-\text{CH}_2-$), 177.25 ($-\text{NHCOCH}_2\text{CH}_2$).

^{31}P NMR (242.7 MHz, $\text{MeOH}-\text{D}_4$) δ_{P} : 13.13 (s).

HR-ESI-MS (m/z) calculated for $\text{C}_{56}\text{H}_{105}\text{N}_6\text{O}_{20}\text{PS}$ $[\text{M}+\text{H}]^+$ 1246.65, found 1246.6960.

Protected phospho-oseltamivir-biotin conjugate 4

Under an atmosphere of dry nitrogen, azide **3**^o (29 mg, 0.052 mmol) was dissolved in dry THF (1 mL) and PMe_3 (1 M stock solution in THF, 68 μL) was added dropwise with stirring. When tlc indicated the absence of starting material (~ 4h), the reaction was quenched with deionised water (0.5 mL) and the mixture was stirred for an additional 30 minutes. The solvent was then removed *in vacuo* and the crude product was placed on a short silica plug (DCM/MeOH; 10:1 +3% NEt_3) to give the respective amine without additional purification. d-Biotin (51 mg, 0.060 mmol) and PyBOP (32 mg, 0.062 mmol) were dried *in vacuo* and then placed under an N_2 (g) atmosphere. Dry DMF (1 mL) was then added followed by DIPEA (16 μL , 0.0974 mmol). The reaction flask was then sonicated briefly and cooled to 0 °C (ice-bath). After a few minutes the isolated amino-conjugate (23 mg, 0.0487 mmol) was dissolved in dry DMF (1 mL) and was added dropwise to the stirring d-Biotin solution. The solution was allowed to warm slowly to room temperature overnight after which time TLC indicated the reaction was complete. The solvent was evaporated *in vacuo* and then purified by flash

chromatography (EA/MeOH; 1:2 + 2% AcOH) to give protected target compound **4** (46 mg, 56%). R_f : 0.4 (EA/MeOH; 1:2 + 2% AcOH).

^1H NMR (500 MHz, MeOH- d_4) δ_{H} : 0.84, 0.96 (6 H, 2t, $J = 7.4$ Hz, $-\text{OCH}(\text{CH}_2\text{CH}_3)_2$), 1.43 (9 H, s, $-\text{NHCOC}(\text{CH}_3)_3$), 1.34 – 1.78 (18 H, bm, $-\text{OCH}(\text{CH}_2\text{CH}_3)_2$, $-\text{C}(\text{O})\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{OCH}_2\text{CH}_2-\text{CH}_2\text{CH}_2-\text{CH}_2\text{CH}_2\text{NH}-$), 1.92 (3 H, s, $-\text{NHCOCH}_3$), 2.24 (2 H, dd, $J = 6.4$ Hz, $-\text{C}(\text{O})\text{CH}_2-$), 2.24 (1 H, m, $\text{H}_{6\text{ax}}$), 2.51 (1 H, m, $\text{H}_{6\text{eq}}$), 2.72, 2.93 (2 H, d, dd, $J = 12.7, 4.7, 12.6$ Hz, $-\text{S}-\text{CH}_2-$), 3.16-3.24 (3 H, m, $-\text{CH}_2\text{CH}_2\text{NH}-$, $-\text{S}-\text{CH}-$), 3.41 (1 H, m, $-\text{OCH}(\text{CH}_2\text{CH}_3)_2$), 3.55 (4H, m, $-\text{OCH}_2\text{CH}_2\text{NHCO}-$, $-\text{NHCOCH}_2\text{CH}_2\text{O}-$), 3.63-3.66 (m, 47H, $-\text{OCH}_2\text{CH}_2\text{O}-$, $\text{P}(\text{O})\text{OCH}_3$), 3.72 – 3.74 (5 H, m, $-\text{OCH}_2\text{CH}_2\text{NHCO}-$, $-\text{NHCOCH}_2\text{CH}_2\text{O}-$, H_5), 3.86 (1 H, m, H_4), 4.00 – 4.14 (3 H, m, $-\text{OCH}_2\text{CH}_2-$, H_3), 4.31 (1 H, dd, $J = 4.3, 7.4$ Hz, $-\text{S}-\text{CH}-\text{CH}-\text{NHCO}-$), 4.51 (1 H, dd, $J = 5.8, 6.0$ Hz, $-\text{S}-\text{CH}_2-\text{CH}-\text{NHCO}-$), 6.57 (1 H, d, $J_{\text{P-2}} = 22.0$ Hz, H_2).


^{13}C NMR (151 MHz, MeOH- d_4) δ_{C} : 9.71, 10.02 ($-\text{OCH}(\text{CH}_2\text{CH}_3)_2$), 23.05 ($-\text{NHCOCH}_3$), 26.43, 26.86, 26.93, 29.60, 29.86, 30.37 ($\text{C}(\text{O})\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{OCH}_2\text{CH}_2-\text{CH}_2\text{CH}_2-\text{CH}_2\text{CH}_2\text{NH}-$), 27.36, 27.53 ($-\text{OCH}(\text{CH}_2\text{CH}_3)_2$), 28.81 ($-\text{NHCOC}(\text{CH}_3)_2$), ~31.4 (d, $J = 5.9$ Hz, $-\text{OCH}_2\text{CH}_2-$), 32.1, 36.86, 40.23 ($-\text{CH}_2\text{CH}_2\text{NH}-$, biotin-C, C_6), 41.07 (biotin-C), 50.4 (C_5), 53.4 (d, $J = 5.8$ Hz, $-\text{P}(\text{OCH}_3)_2$), 56.60 (m, C_4), 57.08, 61.70, 63.45 (biotin-C), 67.84, 68.29, 70.68, 71.39, 71.41, 71.51, 71.56, 71.62, 71.64 ($-\text{OCH}_2\text{CH}_2\text{O}-$, $-\text{OCH}_2\text{CH}_2\text{NH}-$, $-\text{POCH}_2-$, $-\text{NHCOCH}_2\text{CH}_2-$), 77.4 (C_3), 80.39 ($-\text{NHCO}\text{C}(\text{CH}_3)_2$), 83.89 ($-\text{OCH}(\text{CH}_2\text{CH}_3)_2$), 144.32 (C_2), 157.97 ($-\text{NHCO}\text{C}(\text{CH}_3)_2$), 166.15 ($-\text{NH}-\text{C}(\text{O})-\text{NH}-$), 173.88 ($-\text{NHCOCH}_3$), 176.18 ($-\text{CH}_2-\text{C}(\text{O})\text{NH}-\text{CH}_2-$).

^{31}P NMR (161.7 MHz, MeOH- d_4) δ_{P} : 19.00 (s).


HR-ESI-MS (m/z) calculated for $\text{C}_{62}\text{H}_{115}\text{N}_6\text{O}_{22}\text{PS}$ $[\text{M}+\text{Na}]^+$ 1381.75, found 1381.7471.

NMR-Spectra


¹H-NMR Spectrum Compound 1




¹³C-NMR Spectrum Compound 1




31P-NMR Spectrum Compound 1



1H-NMR Spectrum Compound 4



¹³C-NMR Spectrum Compound 4



³¹P-NMR Spectrum Compound 4

